UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.38-14, Article 38

2019

Volltextzugriff (PDF)

Assessing Similarity Among Individual Tumor Size Lesion Dynamics: The CICIL Methodology

CPT: pharmacometrics and systems pharmacology, 2018-04, Vol.7 (4), p.228-236

2018

Volltextzugriff (PDF)

The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib

Blood, 2011-05, Vol.117 (18), p.4999-5008

2011

Volltextzugriff (PDF)

Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20627-e20627

2016

Volltextzugriff (PDF)

Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway

Kidney international, 2001-07, Vol.60 (1), p.83-86

2001

Volltextzugriff (PDF)

Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

Seminars in thrombosis and hemostasis, 2005-08, Vol.31 (4), p.400-403

2005

Volltextzugriff (PDF)

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1137-1145

2004

Volltextzugriff (PDF)

Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT217-CT217

2021

Volltextzugriff (PDF)

Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor

The Journal of pharmacology and experimental therapeutics, 2002-03, Vol.300 (3), p.952-957

2002

Volltextzugriff (PDF)

Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

Seminars in thrombosis and hemostasis, 2005-08, Vol.31 (4), p.400-403

2005

Volltextzugriff (PDF)

Abstract 4522: Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4522-4522

2020

Volltextzugriff (PDF)

Abstract LB-021: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-021-LB-021

2019

Volltextzugriff (PDF)

Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: Pharmacokinetic and pharmacodynamic considerations

Clinical pharmacokinetics, 2004, Vol.43 (14), p.963-981

2004

Volltextzugriff (PDF)

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease

Clinical pharmacology and therapeutics, 2003-03, Vol.73 (3), p.232-241

2003

Volltextzugriff (PDF)

Anticoagulation With Argatroban for Elective Percutaneous Coronary Intervention: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationship of Coagulation Parameters

Journal of clinical pharmacology, 2011-06, Vol.51 (6), p.805-818

2011

Volltextzugriff (PDF)

Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3505-3505

2014

Volltextzugriff (PDF)

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

Clinical pharmacology and therapeutics, 2002-03, Vol.71 (3), p.176-185

2002

Volltextzugriff (PDF)

A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants

Biomicrofluidics, 2013-09, Vol.7 (5), p.56502-56502

2013

Volltextzugriff (PDF)

408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A248-A248

2020

Volltextzugriff (PDF)

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC: Topic: IT Clinical

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1333-S1334

2017

Volltextzugriff (PDF)

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1333-S1334

2017

Volltextzugriff (PDF)

Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions

Platelets (Edinburgh), 2010, Vol.21 (1), p.60-66

2010

Volltextzugriff (PDF)

The Direct Thrombin Inhibitor Argatroban: A Review of Its Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships

Seminars in thrombosis and hemostasis, 2008-10, Vol.34 (S 01), p.75-80

2008

Volltextzugriff (PDF)

Flow cytometric measurement of platelet- leukocyte aggregates : A possible target to monitor platelet function?: Reliability of platelet function tests and drug monitoring

Seminars in thrombosis and hemostasis, 2005, Vol.31 (4), p.400-403

2005

Volltextzugriff (PDF)

Phenotypic differences of human neutrophils of carriers of the PSGL-1 A and B-allele in binding to immobilised P-selectin under flow conditions

Thrombosis research, 2011-02, Vol.127 (2), p.105-110

2011

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

ThemaBlood Platelets - Drug Effects

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(42)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Assessing Similarity Among Individual Tumor Size Lesion Dynamics: The CICIL Methodology

The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib

Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis

Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway

Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor

Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

Abstract 4522: Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist

Abstract LB-021: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors

Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: Pharmacokinetic and pharmacodynamic considerations

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease

Anticoagulation With Argatroban for Elective Percutaneous Coronary Intervention: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationship of Coagulation Parameters

Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants

408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC: Topic: IT Clinical

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC

Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions

The Direct Thrombin Inhibitor Argatroban: A Review of Its Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships

Flow cytometric measurement of platelet- leukocyte aggregates : A possible target to monitor platelet function?: Reliability of platelet function tests and drug monitoring

Phenotypic differences of human neutrophils of carriers of the PSGL-1 A and B-allele in binding to immobilised P-selectin under flow conditions

Aktive Filter

Suchergebnisse filtern